1998: B.SC (Hons) Biochemistry.
Newcastle University
2001: Ph.D Molecular Biology
Urology Research Group
School of Surgical and Reproductive Sciences
Newcastle University
2001- 2006: Post-Doctoral Research Associate.
Urology Research Group,
Northern Institute For Cancer Research,
Newcastle University.
Funded by the Association for International Cancer Research (AICR)
British Association for Cancer Research (BACR)
Endocrine Society
British Association for Cancer Research Young Translational Scientist Award 2006
1. Mechanisms of Androgen Receptor (AR) Regulation in Prostate Cancer
2. Epigenetics and Transcription of AR and Estrogen Receptor (ER)
Histone methyltransferases (HMTs), histone acetyltranferases (HATs) and the enzymes that reverse the effects of these proteins play a fundamental role in regulating transcription. My group are currently deciphering the roles of the HMT SET9 and histone demethylase enzyme JMJD2B in AR and ER regulation in prostate and breast cancer development.
We are also assessing interplay between SET9 and members of the HAT and histone deacetylase (HDAC) families in an attempt to establish ordered mechanisms of co-regulator function during AR-mediated transcription that could provide novel therapeutic targets for prostate cancer treatment.
The group is currently collaborating with AstraZeneca to decipher the molecular function of a novel series of prostate cancer treatments currently in Phase I clinical trials
1 Marie-Curie-funded Ph.D student
1 Masters of Research (MRes) student.
Invited Speaker:
1. Institute of Medical Technology Research Day 2006, University of Tampere, Finland.
2. National Cancer Research Institute (NCRI) 2006, International Conference Centre, Birmingham.
3. Androgens 2006, University of Cambridge.
Cancer Research UK: Funding one PhD student (2010-2014) and one post-doctoral research scientist (August 2011-2014)
Medical Research Council: Funding one post-doctoral research associate (2008-2011)